Past Press Releases
📰 PRESS RELEASE
For Immediate Release
July 31, 2025
Project Eve Launches: New Health Intelligence Platform Targets the Overlooked Collision of Autoimmunity and Menopause
Washington, D.C. – July 31, 2025 – Millions of women living with autoimmune conditions are entering perimenopause or menopause without tailored guidance, data, or care protocols. Project Eve, a newly launched platform co-led by national health policy advisor Cynthia Adinig and digital health executive Tracey Welson-Rossman, is stepping in to close this dangerous gap.
What makes Project Eve different isn't just its AI-powered insight engine or clinical audit tools, it’s who built it. Both founders live with immune-based chronic illnesses and are actively navigating perimenopause or menopause themselves. This unique combination of lived experience and national leadership informs every aspect of the platform, from informed consent to how symptom flares and hormone shifts are modeled in real-world conditions.
"Our health system has never comprehensively studied how hormone changes during midlife alter medication response or autoimmune activity," said Adinig. “We’re not just filling a research gap, we’re rebuilding the entire template.”
The platform is now recruiting participants for its first testing cohort. This phase will focus on real-world symptom mapping, AI calibration, and the creation of digital tools that meet the lived realities of midlife women facing complex health challenges.
Project Eve is now available as a private beta for qualified testers. Public launch is expected later this year.
About Project Eve
Co-created by CYNAERA and Journal My Health, Project Eve is an independent digital health platform focused on closing the data, care, and access gaps for women with autoimmune illness during perimenopause and menopause. The platform blends AI-powered analysis with firsthand insight from women who understand the persistent inadequacy surrounding their care. Our core value is trust, built on transparency, autonomy, and consent.
Sign Up:
https://www.cynaera.com/project-eve
Press Contact:
Email: cynthia@cynera.com
Related Partners:
www.cynaera.com
www.journalmyhealth.com
Past Press Release
📰 PRESS RELEASE
For Immediate Release
June 29, 2025
CYNAERA Launches Nation’s First AI Digital Twin Platform Focused on Chronic Illness Remission and Predictive Care
Northern Virginia — CYNAERA, the AI-powered systems firm founded by federal health advisor and Long COVID researcher Cynthia Adinig, has launched the first comprehensive digital twin platform designed to simulate remission, predict health destabilization, and model chronic illness trajectories using real-world, precision-centered data.
This platform brings together over a dozen proprietary algorithms to form a living, responsive model of patient health—capable of adapting to unique biological patterns across adult, pediatric, rural, and women’s health populations.
“Chronic illness care has historically lacked tools that reflect the complexity of individual patients,” said Cynthia Adinig, Founder of CYNAERA and former member of the Secretary’s Advisory Committee on Long COVID at HHS. “Our platform addresses that gap by modeling how conditions evolve, stabilize, or worsen over time, before clinical records can reflect it.”
Designed for the Gaps Traditional Systems Don’t Capture
Digital twin technologies have been widely adopted in fields like aerospace, climate modeling, and infrastructure—but healthcare implementations have primarily centered on billing optimization and population averages.
CYNAERA’s model is built differently. It centers individual symptom pathways, hormone-immune interactions, and environmentally triggered relapses, offering a predictive advantage for conditions often underrecognized in traditional research, such as Long COVID, ME/CFS, MCAS, POTS, and post-viral dysautonomia.
The platform also identifies diagnostic vulnerabilities common in rural settings, female-presenting patients, and pediatric cases, groups often delayed or mischaracterized in standard care algorithms.
Beyond Big Data: A Technical Breakthrough in Remission Simulation
While platforms like Palantir, Epic, and Google Health provide high-volume health analytics, they are not optimized to detect remission signals, flare predictors, or real-time risk shifts for multi-system illness.
CYNAERA’s digital twin platform introduces a new category of healthcare AI, designed not only to monitor decline but to identify stabilization thresholds and simulate millions of intervention pathways across real-world conditions.
“This system does not replicate the traditional EHR. It augments it, providing a layer of insight that is biologically adaptive and contextually responsive,” Adinig explained.
Platform Modules Now Available for Licensing
The platform’s architecture includes:
-
SymCas™ – Predictive engine for flare events based on time-sequenced symptom data
-
STAIRS™ – Stabilization framework that identifies patients nearing recovery thresholds
-
VitalGuard™ – Environmental risk monitor factoring air quality, mold, humidity, and climate
-
NeuroVerse™ – AI-assisted neuroinflammation symptom clustering
-
US-CCUC™ – Epidemiologic correction model for undercounted chronic conditions
-
SILENZR™ – Detection and compensation model for pediatric and rural data suppression
-
BRAGS™ – Accountability scoring tool for inclusion and diagnostic pattern recognition in clinical trials
Licensing Now Open on CYNAERA Market™
Due to the integrated nature of the digital twin engine, full replication is available only via custom enterprise intelligence packages. However, select modules are available for direct licensing on the CYNAERA Market™, an online portal for research teams, advocacy groups, health systems, and public health agencies.
The platform also incorporates a “Give One, Power One™” model to ensure accessibility: for every licensed module, CYNAERA provides the same capability at no cost to a grassroots or underfunded advocacy group.
About CYNAERA
CYNAERA is a systems-based AI intelligence firm dedicated to predictive modeling, precision diagnostics, and public health strategy for complex chronic conditions. Founded by award-winning researcher and national policy advisor Cynthia Adinig, CYNAERA works with institutions, government agencies, and medical innovators to address the access hurdles in healthcare infrastructure and accelerate early detection and stabilization pathways for vulnerable populations.
Media Contact:
Cynthia Adinig, Founder
📧 cynthia@cynaera.com
🌐 https://www.cynaera.com
🔗 linkedin.com/in/cynthiaadinig
Past Press Release
FOR IMMEDIATE RELEASE
Northern Virginia — May 5, 2025
Federal Health Policy Advisor Discovers First Path to Remission for Long COVID, ME/CFS, and 50+ Chronic Conditions — Built in 4 Months, Featuring Breakthrough Gene Editing Platform CRISPR Remission™
Contact:
Cynthia Adinig, Federal Policy Advisor & Advocate
Email: cynthia@cynaera.com
Website: www.cynaera.com
Northern Virginia, May 2025 – Cynthia Adinig, a federal policy advisor appointed under the Biden administration and a nationally recognized Long COVID advocate, has identified the first systematized path to remission for infection-associated chronic conditions, including Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS). She built the entire model in under four months after witnessing deep cuts to NIH funding and the quiet rollback of several federal initiatives, including the Office of Long COVID.
“I built it because the agencies we counted on to solve this started walking away,” said Adinig. “After watching the NIH defund key workstreams and seeing programs dissolve without warning, I realized: no one was coming. So I did it myself, and I did it in four months.”
What began as a mission to save her own life has now become a clinical platform preparing for early trial partnerships and a roadmap for tackling the conditions science has left unresolved for decades.
A Model Built in Months, Not Years
While major institutions spent years circling symptom clusters, Adinig designed a remission framework grounded in lived experience, AI-powered terrain modeling, and deep pattern recognition across complex chronic illness. Her model moved from concept to pre-pilot in under 120 days, bypassing bureaucratic timelines and centering patient survival as the innovation driver.
Her white paper, The Science of Remission, outlines the framework and its real-world application. It includes stabilization strategies, digital trial simulations, and a new CRISPR-based therapeutic model designed to finally address the biological root causes of chronic multisystem disease.
About the Discovery
The model was developed through CYNAERA, the AI-driven systems research firm Adinig founded to accelerate chronic illness innovation. Her IACC Terrain Model™ identifies four key disruptions, immune dysregulation, mitochondrial dysfunction, autonomic instability, and neuroinflammation and maps their sequence, intensity, and intervention potential across millions of patient profiles.
Complementing this, CYNAERA introduced the Composite Diagnostic Fingerprint (CDF), a validated, high-specificity diagnostic framework that integrates 12 biomarkers across immunological, neurological, cardiovascular, and metabolic systems, enhanced by digital phenotyping. This approach addresses the diagnostic challenges of Long COVID, especially in cases often misclassified or overlooked, such as pediatric patients or those with mild initial infections. By standardizing diagnosis, the CDF guides personalized treatment and ensures broader access to care.
Her most groundbreaking contribution: the invention of CRISPR Remission™, a new genomic tool that applies CRISPR not to rare inherited mutations, but to dynamic, multisystem dysfunctions caused by post-infectious damage. By targeting immune overactivation, mast cell expression, and autonomic gene signaling, CRISPR Remission™ opens a door to systemic resolution, not just symptom control.
Paired with CYNAERA’s STAIR Stable Method™ and Clinical Trial Simulator, these tools allow researchers to model and test recovery strategies digitally and safely before human trials begin.
Who Is Behind the Work
Cynthia Adinig is a federal health policy advisor, strategist, and patient advocate who played a key role in shaping bipartisan Long COVID legislation, including early contributions to the COVID-19 Long Haulers Act. She has worked directly with members of Congress across the aisle, including longstanding collaborations with Senator Tim Kaine, who also lives with Long COVID.
Adinig served as an advisor to the Mt. Sinai CORE, under Dr. David Putrino. She currently contributes to the T-cell immunology research team led by Dr. Liisa Selin at UMass Chan Medical School and is a co-author of research publications with investigators from Mt. Sinai, Yale, and the University of South Carolina, bringing scientific, immunological, and patient-centered insight to the research pipeline.
She has advised the U.S. Department of Health and Human Services, testified before Congress, and worked with national institutions on healthcare access and systems reform. She is the co-founder of the BIPOC Equity Agency, a board member at Solve ME.
“This is personal, but it’s also national. My son Aiden has Long COVID. I built this so he wouldn’t have the same experience I did.”
Why This Matters
More than 100 million people worldwide are estimated to live with infection-associated chronic conditions, including Long COVID, ME/CFS, POTS, MCAS, and chronic Lyme. In the U.S. alone, Long COVID pushed over 4 million people out of the labor force at its peak. The total economic cost is estimated at $3.7 trillion, according to the Brookings Institution.
But the cost isn’t just financial, it’s deeply biological. These immune and inflammatory breakdowns are increasingly linked to elevated cancer risk, particularly among post-viral and chronically inflamed populations. Adinig’s model doesn’t just reverse chronic illness, it may also help stabilize pre-cancerous immune terrain, offering new paths to prevention and immune recalibration.
“We’ve watched post-viral illness explode and now we’re seeing cancer follow,” said Adinig. “If we can stabilize the terrain early, we may prevent both.”
What’s Next
CYNAERA is onboarding its first pilot cohort of researchers, clinicians, and biotech partners to test the system across conditions. Tools will be available through the CYNAERA Market in Q2 2025. The company is also engaging with select collaborators to prepare CRISPR Remission™ for preclinical modeling and safety validation.
The implications of this work extend far beyond Long COVID and ME/CFS. The same immune terrain disruptions addressed by CRISPR Remission™, chronic inflammation, immune exhaustion, autonomic dysfunction, are central to cancer progression, HIV persistence, and emerging neurodegenerative diseases like MS, and Alzheimer’s. CYNAERA’s framework offers a new playbook for accelerating recovery and immune recalibration across some of the most intractable diseases of our time.
“I designed this to reverse Long COVID, but the implications go much further,” said Adinig. “We may be able to stabilize immune terrain for cancer, HIV, and even Alzheimer’s. I’m not just treating symptoms, I’m redesigning how we recover.”
To access the white paper or request partnership information, visit www.cynaera.com
Press Contact:
Cynthia Adinig
cynthia@cynaera.com